The deposition of aggregated amyloid-β peptides derived from the pro-amyloidogenic processing of the amyloid precurson protein (APP) into characteristic amyloid plaques (APs) is distinctive to Alzheimer's disease (AD). Alternative APP processing via the metalloprotease ADAM10 prevents amyloid-β formation. We tested whether downregulation of ADAM10 activity by its secreted endogenous inhibitor secreted-frizzled-related protein 1 (SFRP1) is a common trait of sporadic AD. We demonstrate that SFRP1 is significantly increased in the brain and cerebrospinal fluid of patients with AD, accumulates in APs and binds to amyloid-β, hindering amyloid-β protofibril formation. Sfrp1 overexpression in an AD-like mouse model anticipates the appearance of APs and dystrophic neurites, whereas its genetic inactivation or the infusion of α-SFRP1-neutralizing antibodies favors non-amyloidogenic APP processing. Decreased Sfrp1 function lowers AP accumulation, improves AD-related histopathological traits and prevents long-term potentiation loss and cognitive deficits. Our study unveils SFRP1 as a crucial player in AD pathogenesis and a promising AD therapeutic target.
A D, a devastating condition and a worldwide leading cause of dementia 1 , exists in two forms: a rare genetic form of early onset caused by mutations in a few genes (APP, PS1, PS2); and a sporadic, late onset, slowly progressing and common form, for which age is the most accepted risk factor 2 . By 2050, sporadic AD is expected to affect 150 million individuals worldwide, becoming an unsustainable socio-economical problem. The urgent need for an effective treatment has spurred a large number of clinical trials 3 , many of which have targeted one of the most salient disease hallmarks: the accumulation of amyloid-β peptides in the form of extracellular APs 1, 4 . Amyloid-β peptides are produced mainly in neurons via sequential processing of APP by β-and γ-secretase, although it is unclear whether this is the primary cause of the disease or its consequence 5 . Notwithstanding, reducing/blocking the different amyloid-β forms seems to delay the disease in animal models and to slow clinical decline in patients with prodromal or mild AD. Unfortunately, the disease is not arrested 6, 7 , perhaps because the factors that favor amyloid-β production and trigger their aggregation in toxic forms are still not fully understood 1 . ADAM10, the constitutive α-secretase of the brain 8 , cleaves APP within the amyloid-β sequence blocking the generation of toxic peptides and releasing a soluble extracellular fragment, known as sAPPα 9 . Mutations in the ADAM10 pro-domain, which lower its α-secretase activity and shift APP processing towards the proamyloidogenic pathway 10 , cosegregate with some AD cases 10, 11 . This raises the possibility that impaired ADAM10 activity might be among the common triggers of amyloid deposition, contributing to AD pathogenesis.
Here, we tested this possibility focusing on SFRP1, a small (35 kDa) secreted and highly dispersible protein 12 composed of two domains, one of which has homology with tissue inhibitors of metalloproteases 13 . Sfrp1 has a dual function: modulation of Wnt signaling 13 and regulation of the enzymatic activity of ADAM10 (ref. 14 ). SFRP1 is expressed in the CNS and downmodulates the proteolytic processing of all the ADAM10 substrates so far tested, including APP [14] [15] [16] , thus being the only endogenous ADAM10 regulator hitherto described 14 . We hypothesized that upregulation of SFRP1 levels in the brains of patients with AD could enhance pro-amyloidogenic APP processing and the cascade of stereotyped brain alterations that, in addition to AP deposition, include synaptic dysfunction, brain inflammation and the formation of dystrophic neurites, among others traits 1 . By combining studies in human AD cases and in mouse models, we demonstrated that SFRP1 is a novel player in AD pathogenesis. Mechanistically, SFRP1 interferes with Articles NATuRe NeuROScieNce neuronal ADAM10-mediated anti-amyloidogenic APP processing and further interacts with amyloid-β peptides hampering the formation of amyloid-β protofibrils. Antibody-mediated neutralization of SFRP1 activity suffices to prevent synaptic dysfunction, pointing to a novel therapeutic avenue worthy of being explored.
Results
SFRP1 levels in patients with AD positively correlate with amyloidogenic APP processing. With the aim of determining whether SFRP1 levels are elevated in the brains of patients with AD, we first generated α-SFRP1 monoclonal antibodies and developed a specific and sensitive enzyme-linked immunosorbent assay (ELISA; Fig. 1 | SFRP1 is upregulated in human samples from patients with AD, correlating with pro-amyloidogenic APP processing. a,c, ELISA determination of SFRP1 protein levels in TBS-and RIPA-soluble fractions of entorhinal (a) and frontal (c) cortex from controls and patients with AD at different BB stages as indicated in the graphs. Data were analyzed with two-way ANOVA followed by Bonferroni test. *P < 0.05; **P ≤ 0.01; ****P ≤ 0.0001 (entorhinal cortex, n = 8; soluble fraction: I-II versus C, P = 0.0011; III-IV versus C, P = 0.0001; RIPA fraction: III-IV versus C, P = 0.0217, V-VI versus C, P = 0.01; frontal cortex, n = 7; RIPA fraction: V-VI versus C, P = 0.00319). b,d, Fold enrichment of SFRP1 mRNA levels in the entorhinal (b) and frontal (d) cortex of AD at different BB stages when compared with controls. Values were determined by Taqman PCR assays, normalized against the levels of HPRT and AARS housekeeping genes. Results were analyzed with Kruskal-Wallis test followed by post hoc Mann-Whitney U-test. Differences between groups were considered statistically significant at *P ≤ 0.05; **P ≤ 0.01 (entorhinal cortex: control n = 6, I-II n = 5, III-IV n = 4, V-VI n = 5; frontal cortex: control n = 11, I-II n = 5, III-IV n = 8, V-VI n = 20). e,f, Scatter plot of Aβ42 (e) and sAPPα (f) versus SFRP1 levels in samples of human entorhinal cortex. SFRP1, Aβ42 and sAPPα levels were determined by specific ELISA on the same samples. Note the significant positive correlation between SFRP1 and Aβ42 levels (e) and the tendency towards a negative correlation between SFRP1 and sAPPα (f). The data were analyzed with a linear regression method. g, ELISA-based determination of sAPPα levels in human control (n = 5) and AD entorhinal (n = 13) cortex extracts. Data are means ± s.e.m. analyzed with two-sided Student's t-test, ***P ≤ 0.001. h, SFRP1 levels in CSF samples from cohorts of patients with AD (n = 40) and age-matched controls (n = 43; Supplementary Table 2) . Data are means ± s.e.m. analyzed with two-sided t-test; significance is indicated in the graph. i-m, Confocal images of frozen sections from the frontal cortex of patients with AD (BB V-VI) co-immunostained with antibodies against SFRP1 (red) and amyloid-β (clone 6E10) (i-k), GFAP (l) or Iba1 (m) (all in green). In each row, single and merged channels are shown. Note that SFRP1 accumulates in the core of the Aβ+ plaque (arrowheads in i, j), forms aggregates in the AP halo (arrow in j), is associated to blood vessels (k) and localizes to GFAP+ (arrowhead in l) and Iba1+ cells (arrowhead in m; see also Supplementary Videos 1 and 2). These experiments were repeated three times obtaining similar results. Scale bar, 50 μm.
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NATuRe NeuROScieNce Supplementary Fig. 1 ). Application of this ELISA showed a correlation between AD pathological state and SFRP1 upregulation. Indeed, SFRP1 protein was elevated in both the Tris-buffered saline (TBS)-and radioimmunoprecipitation assay (RIPA)-soluble fractions of entorhinal and frontal cortex extracts from patients with AD at presymptomatic, mild and advanced neuropathological stages of the disease (Braak and Braak (BB) I-II/0-A; III-IV/0-C; V-VI/B-C; Supplementary Table 1) , when compared to age-matched control samples (Fig. 1a,c) . The increase was particularly evident in both fractions of the entorhinal cortex at early and intermediate disease stages, but less so in the soluble fraction at late stages, when SFRP1 levels were instead the highest in the RIPA fraction (Fig. 1a) . The SFRP1 increase observed in the soluble fraction positively correlated with the amount of amyloid-β Aβ42 found in the same extracts (Fig. 1e) , whereas there was only a tendency towards a negative correlation when plotted against the levels of sAPPα (Fig. 1f ) measured in the same samples. Nevertheless, sAPPα levels were significantly lower in extracts from patients with AD (37.75 ± 5.299, n = 13) than those of controls (97.74 ± 19.83; n = 5; P ≤ 0.001; Fig. 1g) . A tendency toward amyloidogenic APP processing was further confirmed by western blot analysis of extracts from entorhinal cortical samples of patients with AD as compared to those from agematched controls ( Supplementary Fig. 2a-e) .
SFRP1 protein increase was paralleled by its transcriptional upregulation especially at BB V-VI in a similar characterized cohort of patients with AD and age-matched controls (Fig. 1b,d) , with no parallel significant changes in the expression of BACE1, APP and ADAM10 at least at BB I-II and ( Supplementary Fig. 2f ). Furthermore, an in silico search found that SFRP1 was listed among the genes with a progressive enhanced hippocampal expression in patients with incipient or advanced AD (supplementary information in ref. 17 ). Immunohistochemical analysis of the human frontal cortex from patients with AD revealed a consistent SFRP1 immunoreactivity in auto-fluorescent elastin+ 18 blood vessels ( Supplementary Fig. 3a ,b) colocalizing with amyloid-β deposits (Fig. 1k) . SFRP1 was also present in some GFAP+ reactive astrocytes surrounding the APs (Fig. 1l and Supplementary Video 1) and in activated Iba1+ microglia infiltrated in the APs (Fig. 1m and Supplementary Video 2). By contrast, immuno-positive signal was undetectable in the cortex of control individuals ( Supplementary Fig. 3d ), although SFRP1 was found in extracts of the choroid plexus at levels similar to those found in samples from AD individuals (Supplementary Fig. 3e ). The choroid plexus is the main source of cerebrospinal fluid (CSF) proteins and its function is unbalanced in patients with AD 19 . We therefore measured SFRP1 content in CSF samples of another characterized cohort patients with AD and control individuals (Supplementary Table 2 ), finding a significantly higher protein concentration in patients than in controls (Fig. 1h) .
Together these data demonstrate a correlation between elevated SFRP1 content and the presence of AD. SFRP1 accumulates in APs and binds to amyloid-β hindering the formation of amyloid-β protofibrils. Of note, immunohistochemical analysis revealed a strong and specific accumulation of SFRP1 also in the core of Aβ+ (Fig. 1i,j and Supplementary Fig.  3f ; staining with the 6E10 monoclonal antibody) and ThioS+ plaques (APs; Supplementary Fig. 3g ). Positive signal was also observed in the AP halo ( Fig. 1j, arrow; Supplementary Fig. 3f,g,  arrows) , where small amyloid-β oligomers seem to localize 20 , and in ThioS-negative aggregates ( Supplementary Fig. 3h ). This distribution appeared to be AD related, as it was never observed in control brains ( Supplementary Fig. 3d ).
Together these observations suggested a possible interaction between SFRP1 and amyloid-β peptides as well as potential formation of SFRP1 aggregates. To explore these possibilities, we performed in vitro aggregation assays followed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis with antibodies against SFRP1 and amyloid-β. Indeed, the two molecules formed SDS-resistant complexes with molecular weights compatible with combinations of both SFRP1 and Aβ1−42 multimers (Fig. 2a,b) . Binding between the two molecules was apparently stronger than that previously reported between Aβ1−42 and albumin 21 ( Supplementary Fig. 4a,b) . Because SDS-PAGE can only resolve relatively low molecular weight amyloid-β aggregates 22, 23 , we . c-e, Transmission electron microscopic analysis of Aβ1-42 (c) and SFRP1 (e) alone or in combination (d) after incubation at 37 °C for the indicated times. Note that SFRP1 favors the oligomeric (red arrows) versus protofibrillary (black arrows) form of Aβ1-42. SFRP1 alone also tends to aggregate (e). All experiments were repeated three times, obtaining similar results. Scale bar, 80 nm.
NATuRe NeuROScieNce used transmission electron microscopy (TEM) analysis to determine the possible time-dependent formation of larger Aβ1−42 and SFRP1 aggregates (Fig. 2c-e and Supplementary Fig. 4c ). Amyloid-β alone formed aggregates following the path described for amyloid proteins [24] [25] [26] , from small oligomers to large protofibrils ( Fig. 2c and Supplementary Fig. 4c ). SFRP1 alone also appeared to oligomerize over time but in a disordered manner, giving rise to spherical structures of different sizes ( Fig. 2e and Supplementary Fig. 4d ). In notable contrast, when the two proteins were incubated together, the latter structures and the protofibrils were no longer visible ( Fig. 2d and Supplementary Fig. 4c ). To further corroborate these findings, we used dot blot analysis of different concentrations of Aβ1-42 and SFRP1 mixtures probed with antibodies to detect the presence and relative abundance of Aβ1-42 fibril/protofibril forms (OC antibody) and low molecular weight amyloid oligomers (A11, conformation antibody). This analysis confirmed that Aβ1-42 fibril/ protofibril forms increased with time but their relative abundance was lower in the presence of SFRP1 in a concentration-dependent manner ( Supplementary Fig. 4d ). Conversely, oligomeric Aβ1-42 forms appeared to prevail in the presence of SFRP1 ( Supplementary  Fig. 4d ), supporting TEM observations. Unexpectedly, the A11 antibody recognized SFRP1 alone ( Supplementary Fig. 4d ), raising the possibility that the protein might acquire amyloid characteristics, at least in vitro.
Together these data suggest that the two proteins influence each other's aggregation: amyloid-β prevents the formation of SFRP1 spherical structures and SFRP1 limits the formation of Aβ1−42 protofibrils, favouring the presence of oligomeric forms.
Glial-cell-derived Sfrp1 localizes to the synaptic compartment in APP;PS1 mouse brains.
To analyze whether SFRP1 is causally linked to AD progression, we turned to APP;PS1 transgenic mice 27 that are commonly used as a model of amyloidosis. Similar to what is observed in human tissue, a mouse-adapted and specific ELISA using RIPA homogenates from APP;PS1 brains showed an age-dependent significant increase of Sfrp1 levels, already evident in presymptomatic 2-month-old animals ( Fig. 3a,b ), in agreement with what is observed in the entorhinal cortex of BB I-II stage patients (Fig. 1a) . This increase was further confirmed by western blot analysis of brain extracts from APP;PS1 brains ( Supplementary  Fig. 5a ). Co-immunostaining with α-Sfrp1 and glial-specific markers in wild-type (WT; Supplementary Fig. 5b ,c) and APP;PS1 
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NATuRe NeuROScieNce (Fig. 3c,d ) mice showed that Sfrp1 localized to the wall of the lateral ventricle and GFAP+ astrocytes and Iba1+ microglial cells as well as to laminin+ blood vessels ( Supplementary Fig. 5d ,e). As observed in human samples, a strong and very specific Sfrp1+ signal was also detected in Aβ+ and ThioS+ APs (Fig. 3e -h' and Supplementary Fig. 5f -i) and in the choroid plexus of APP;PS1 mice with an intensity that increased with age ( Fig. 3i-k) . Co-immunoprecipitation studies using cortical extracts of 6-month-old APP;PS1 mice confirmed that Sfrp1 and amyloid-β interact in vivo ( Fig. 3l and Supplementary Fig. 6a ).
In APP;PS1 brains, but also in patients with AD, APP expression and processing occurs mostly in neurons 28 , including in the synaptic compartment in which APP and ADAM10 localize 29, 30 ( Fig. 3m ). Consistent with this idea and in contrast to what is observed in WT animals, Sfrp1 was found in the synaptosomal preparations from 8-month-old APP;PS1 mice ( Fig. 3m and Supplementary Fig. 6b ), where it specifically co-immunoprecipitated with ADAM10 ( Fig. 3n and Supplementary Fig. 6c ).
Double RNAScope in situ hybridization (ISH) with probes for Iba1 and Sfrp1 messenger RNA and Sfrp1 ISH coupled to anti-GFAP Data are means ± s.e.m., analyzed with two-sided Student's t-test; ***P = 0.00042. g-l, Frontal cryostat sections from the cortex of 5.5-month-old heterozygous APP;PS1 mice transduced at 2.5 months of age with lentiviruses (LV) carrying GFP (n = 3) (g,i,k) or Sfrp1-IRES-GFP (n = 3) (h,j,l). Sections were co-immunostained for Aβ42, LAMP1 or the activated microglial marker CD45, as indicated in the panels. Scale bar, 100 μm. m,n, Quantification of LAMP1+ area (P = 0.009) and Aβ42+ hotspots (P = 0.0029) in APP;PS1 transduced animals. Data are means ± s.e.m., analyzed with two-sided Student's t-test; *P ≤ 0.05; **P ≤ 0.01.
NATuRe NeuROScieNce further showed that in APP;PS1 brains Sfrp1 is produced in astrocytes, microglial and choroid plexus cells, likely at higher levels than in WT (Fig. 4a-c) . Notably, cells surrounding ThioS+ plaques appeared to express twice as much Sfrp1 mRNA than those located far from the plaques (Fig. 4d-f ). This observation supports the idea that Sfrp1 released by glial cells influences ADAM10 activity in neurons, thereby modulating APP processing.
Forced expression of Sfrp1 in APP;PS1 mouse brains accelerates the appearance of APs. Given that Sfrp1 expression and distribution in APP;PS1 mice mimicked that observed in human AD samples, we next tested if the forced increase of Sfrp1 levels in the brains of young APP;PS1 mice would accelerate AP deposition. We first used heterozygous APP;PS1 mice, because of their late and slow AP build-up 27 . Mice were transduced with lentiviral preparations expressing either GFP (LV-GFP) or Sfrp1 (LV-Sfrp1-IRES-GFP) at 2.5 months of age and analyzed 3 months later. At this final age, Aβ+ APs were barely detectable in the cortex of het-APP;PS1 mice (not shown) or of mice transduced with LV-GFP (Fig. 4g,i,k) . In contrast, mice exposed to LV-Sfrp1-IRES-GFP presented a significant build-up of Aβ+ APs, surrounded by CD45
+ activated microglial cells (Fig. 5h,j,l,m) as commonly observed around APs 31, 32 . There was also an increase in the number and size of accumulations positive for LAMP1 (Fig. 5i ,j,n), a lysosomal glycoprotein that accumulates in dystrophic neurites 31 . A similar effect was observed when 2-month-old homozygous APP;PS1 mice were transduced with either one of the two lentivirus preparations and analyzed 1 month after ( Supplementary Fig. 7a-k) . In LV-Sfrp1-IRES-GFP transduced animals, Aβ+ APs, reactive gliosis and pTau+ dystrophic neurites outnumbered the few found in LV-GFP transduced ( Supplementary  Fig. 7a-k) or non-transduced (not shown) mice.
Together these results support the contention that elevated Sfrp1 levels contribute to AP formation.
Sfrp1 inactivation prevents the appearance of pathological traits in APP;PS1 mice. To further test the link between Sfrp1 and amyloid deposition, we performed the converse experiment using APP;PS1;Sfrp1 −/− mice, generated by crossing the APP;PS1 line with Sfrp1 −/− mice 33 , which are viable, fertile and show no sign of neurodegeneration. Taking advantage of the lacZ reporter present in the Sfrp1 null allele 33 , we first confirmed that both GFAP+ astrocytes and Iba1+ microglial cells, but not NeuN+ neurons, are indeed a source of Sfrp1 ( Supplementary Fig. 7l-n) , particularly abundant in the proximity of ThioS+ APs (Supplementary Fig 7o,p) . Next, we immunostained the cortex of 4.5-, 9-and 20-month-old APP;PS1 and APP;PS1;Sfrp1 −/− mice with an anti-Aβ42 antibody (H31L21) that recognizes only the longer and more pathogenic amyloid-β forms present in APs and the surrounding protofibrillary accumulations 34 . APP;PS1;Sfrp1 −/− cortex developed significantly fewer, smaller and more compact Aβ42+ (Fig. 5a-g and Supplementary  Fig. 8a ) or ThioS+ ( Supplementary Fig. 8b-h ) APs than their APP;PS1 counterparts. Similar results were found in brains of a different group of APP;PS1 and APP;PS1;Sfrp1 −/− mice probed with antibodies that recognize Aβ1-40/42 peptides ( Supplementary  Fig. 8i-m) . In all cases, AP reduction correlated with a comparably significant decrease in LAMP1, Iba1, CD45 and GFAP immunoreactivity (Fig. 5h-s and Supplementary Fig. 9) .
Consistent with the observation that in the absence of Sfrp1 APs are reduced, the amount of Aβ42 present in the RIPA fractions (Fig. 6a ) and the levels of other β-secretase-derived APP fragments, that is CTFβ, present in 6-month-old APP;PS1;Sfrp1 −/− brains were significantly reduced when compared to those of agematched APP;PS1 brains (Fig. 6c,d and Supplementary Fig. 10a-c) , whereas those of sAPPα and CTFα were significantly increased (Fig. 6b ,e,f and Supplementary Fig. 10b,c) . Similarly, the proteolysis of Cdh2, another ADAM10 substrate implicated in synapse stabilization 29 , was also significantly enhanced in APP;PS1;Sfrp1 −/− when compared to APP;PS1 (Supplementary Fig. 10d ). These changes 
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were not related to differences in brain App and Adam10 expression, as the respective mRNA levels were similar in the two genotypes ( Supplementary Fig. 11a) . Similarly, no significant changes in APP, BACE1 and ADAM10 protein expression were detected ( Supplementary Figs. 10a,c and 11b,c) .
Together these data indicate that SFRP1 interacts with ADAM10 in neurons and interferes with the proteolytical processing of APP and Cdh2, as previously shown in other contexts 14, 16 . Thus, in the absence of Sfrp1, APP processing is shifted towards the nonamyloidogenic pathway, decreasing the accumulation of APP toxic forms, in agreement with the idea that α-and β-secretases compete for APP processing 10, 35 . In further support of this interpretation, SFRP1 activity appeared independent from its well-established additional role as a Wnt signaling modulator 13, 36 , given that mRNA and protein levels of Axin2, a read-out of Wnt/βcatenin signaling activation, were comparable in the brains of both genotypes ( Supplementary Fig. 11a,d) .
To determine if Sfrp1 inactivation protects APP;PS1 mice also from the appearance of behavioral deficits, we compared recognition and spatial learning and memory in 8-month-old WT, Sfrp1 −/− , APP;PS1 and APP;PS1;Sfrp1 −/− mice, using the novel object recognition (ORT) and Morris water maze tests. The behavior of Sfrp1 −/− mice was indistinguishable from that of WT mice, with proficient ORT discrimination indexes similar to those reported in other studies 37 and with comparable spatial and locomotor skills ( Supplementary  Fig. 12a-c) . In notable contrast with the already reported 38 and evident cognitive decline observed in APP;PS1, APP;PS1;Sfrp1 −/− mice showed a behavior similar to that of age-matched WT mice in both tests (Fig. 6g,h and Supplementary Fig. 12d ), despite a slightly lower locomotor performance (Supplementary Fig. 12e ).
Together these data indicate that knocking Sfrp1 out largely prevents the appearance of pathogenic characteristics in APP;PS1 mice, strongly delaying their progressive dysfunctions.
Antibody-mediated neutralization of SFRP1 activity counteracts the appearance of AD pathogenic traits in mice. To rule out a possible relation of these results with an Sfrp1 developmental function, we sought to interfere with Sfrp1 activity using a neutralizing monoclonal antibody, given that systemically administered antibodies have been shown to successfully enter and bind to the brain parenchyma 7 . Among the generated monoclonal antibodies, clone 10.5.6 secreted an IgG1 with Sfrp1 neutralizing activity ( Supplementary Fig. 13 ). Biotinylation of the 10.5.6 monoclonal antibody showed that the monoclonal antibody successfully reached the brain parenchyma of APP;PS1 mice 24 h after systemic injection through the retro-orbital sinus, accumulating around Aβ+ plaques ( Supplementary Fig. 14a-f) . Treating 2-month-old APP;PS1 mice with a weekly administration of 10.5.6 monoclonal antibody (100 μg per injection) for 2 months, via the same route, significantly reduced their cortical Aβ42 and ThioS+ AP burden when compared to animals treated with a control unspecific mouse IgG1 (Fig. 7a-d,g,h) , without promoting microglial activation or macrophages infiltration ( Supplementary Fig. 14g-v) , which are the reported secondary effects of some α-amyloid-β immunotherapies 39 . The AP decrease was associated with a comparable significant reduction in the number and size of LAMP1+ accumulations around each APs (Fig. 7e,f,i,j) , indicating that α-Sfrp1 treatment limits the area of dystrophic neurites that contribute to brain degeneration.
In a second set of experiments we treated animals with the same protocol but for three additional months and then tested whether SFRP1 neutralization would rescue synaptic plasticity deficits already documented for the APP;PS1 mice used in this study 40 . Synaptic function was assessed by electrophysiological recordings of field excitatory postsynaptic potential (fEPSPs) between hippocampal CA3 and CA1 cells in acute slices prepared from WT or APP;PS1 treated mice (see representative traces in Fig. 7k ). APP;PS1 animals injected with the control IgG showed a strong impairment in long-term potentiation (LTP), as compared to WT (Fig. 7k-m) . APP;PS1 mice treated with α-Sfrp1 antibodies instead presented a LTP response comparable to that of WT (Fig. 7k-m) .
Taken together these data indicate that antibody-mediated neutralization of SFRP1 activity is sufficient to counteract morphological and functional traits of AD.
Discussion
There are many hypotheses that attempt to explain AD pathogenesis. Among them, the amyloid cascade hypothesis has found strong support from genetic, pathological and biochemical studies 1 . According to this hypothesis amyloid-β production and aggregation has a pivotal role in triggering the cascades of brain alterations that eventually lead to dementia 1 . Nevertheless, why amyloid-β production and aggregation occurs in AD is still not fully understood 4 . Our data unveil the contribution of SFRP1 in these two processes and provide a proof of concept that neutralization of SFRP1 activity counteracts AP formation and synaptic dysfunction observed in AD mice, representing a therapeutic avenue worth exploring.
Our complementary observations in patients with AD and in a mouse model of amyloidosis support a model in which SFRP1, produced and secreted by activated microglia, reactive astrocytes and cells of the choroid plexus, diffuses into the brain parenchyma to interfere with ADAM10-mediated APP processing in neurons, thereby enhancing pro-amyloidogenic APP processing and, thus, the production of toxic amyloid-β products. Notably, SFRP1 accumulates in APs, forms molecular aggregates and interacts with amyloid-β peptides, with the net result of hampering the formation of protofibrillary forms of amyloid-β, which are considered to be less harmful 41 . Amyloid-β formation and aggregation further contribute to activate glial cells 42 and, thus, to further SFRP1 production, suggesting that SFRP1 is part of the feed-forward mechanism that sustains AD pathogenesis (Supplementary Fig. 15 ).
Based on our previous findings that Sfrp1 interacts with ADAM10 and thereby modulates the amount of sAPPα derived from ADAM10-mediated non-amyloidogenic APP processing, we have now shown that in patients with AD SFRP1 levels positively −/− (n = 6) 8-month-old mice subjected to Morris water maze (g) and ORT (h) (extended information in Supplementary Fig. 12 ). Data are means ± s.e.m. analyzed with one-or two-way ANOVA followed by Tukey tests. **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. Uncropped blots are presented in Supplementary Fig. 10 .
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NATuRe NeuROScieNce correlate with the amount of soluble amyloid-β. Conversely, lack of Sfrp1 activity in the brain of APP;PS1 mice strongly reduces soluble amyloid-β peptides and the presence of other products of amyloidogenic APP processing, while increasing the levels of sAPPα. These observations support our model that SFRP1 hinders APP processing by ADAM10, allowing for the production of toxic APP products. This mechanism by itself could explain the observed reduction of APs and neuroinflammation in APP;PS1;Sfrp1 −/− mice as well as . However, the consequences of a diminished ADAM10 activity may not be directly limited to amyloid deposition, as the list of ADAM10 substrates is long 43 . For example, the proteins TREM2 and Fractalkine, critical for microglial activation 42 , and N-cadherin and Neuroligin, involved in synaptic plasticity, are among its well-recognized targets 44 . Besides, ADAM10 genetic inactivation impairs learning and memory 44 . In support of a possible direct implication of SFRP1 in synaptic function, we have shown that SFRP1 immunoprecipitates with ADAM10 in synaptosomal preparations and that the absence or neutralization of Sfrp1 activity has remarkable effects in preventing cognitive loss and synaptic dysfunction.
The interaction of SFRP1 with amyloid-β peptides, its accumulation in APs and its significant upregulation in the brain parenchyma and CSF of patients with AD also advocate for SFRP1 implication in disease pathogenesis. Our studies point to two concomitant mechanisms. Indeed, besides favouring amyloidogenic APP processing, SFRP1 seems to influence amyloid-β aggregation, limiting the formation of Aβ1−42 protofibrils and favouring the presence of oligomeric forms. On the other hand, amyloid-β also seems to prevent the formation of SFRP1 spherical structures and SFRP1 may unexpectedly have amyloid characteristics. The significance of these observations for the time being is a matter of speculation. However, oligomeric forms of amyloid-β have been shown to be toxic for neurons, whereas protofibrillary forms are thought to be less harmful 24, 25 . This raises the possibility that SFRP1 might indirectly increase amyloid-β promoting the existence of its oligomeric forms, a hypothesis that could be tested in the future.
Several anti-amyloid-β immunotherapies have given discouraging results 45, 46 . Nevertheless, recent results obtained either with the administration of a different α-amyloid-β monoclonal antibody (aducanumab) 7 that targets toxic amyloid-β oligomeric forms, or the replacement of plasma albumin, which clears amyloid-β peptides 47 , points to the benefit of decreasing soluble oligomeric amyloid-β and AP burden. In mice, Sfrp1 neutralization results in an effective maintenance of synaptic function without causing harmful macrophage infiltration 39 , providing the proof of concept that lowering Sfrp1 levels has a positive effect, at least when applied at early stages of the disease. Thus, in a speculative view, targeting SFRP1 alone or in combination with other promising anti-amyloid-β strategies 7 may represent a therapeutic avenue for presymptomatic patients with AD, although unwanted side effects remain a possibility. Indeed, SFRP1 acts on different pathways and many of the ADAM10 substrates are implicated in tumor formation and general inflammation 44 . Nonetheless, recent studies have proposed that moderate ADAM10 activation might help in preventing AD onset 48 . SFRP1 is not a full inhibitor but rather a negative modulator of ADAM10 6, a,c,e) or the α-Sfrp1 monoclonal antibody 10.5.6 (n = 6, b,d,f), immunostained as indicated in the panels. Scale bar, 100 μm. g,h, Quantification of the number of ThioS+ (**P = 0.0063) and Aβ42+ (**P = 0.0021) APs present in the cortex of APP;PS1 mice after treatment with IgG1 (n = 7) or α-Sfrp1(n = 9). i,j, The percentage of LAMP1+ area (**P = 0.0028) and the size (*P = 0.0256) distribution of LAMP1+ spots in the cortex of APP;PS1 after treatment with IgG1 (n = 502, from 6 animals) or α-Sfrp1 (n = 132, from 6 animals). Note that Sfrp1 neutralization prevents the appearance of larger LAMP1+ hotspots. Data are means ± s.e.m. analyzed with two-sided Student's t-test, *P ≤ 0.05; **P ≤ 0. RNA purification. RNA was purified with RNeasy Lipid Tissue Mini Kit (Qiagen) following the manufacturer's protocol. Sample concentrations were determined at A260 using a Nanodrop 2000 spectrophotometer (Thermo Fisher). RNA integrity was determined using the Agilent 2100 BioAnalyzer.
Retrotranscription reaction. Samples with RIN (RNA integrity number) values from 6.4 to 9.1 were retro-transcribed in the presence or the absence (to assess genomic DNA contamination) of MultiScribe Reverse Transcriptase using the High Capacity cDNA Archive Kit (Applied Biosystems) following the manufacturer's guidelines and using a Gene Amp 9700 PCR System thermocycler (Applied Biosystems).
TaqMan real-time PCR. TaqMan PCR assays were performed in duplicate in 384-well optical plates using an ABI Prism 7900 Sequence Detection system (Applied Biosystems) and the probes listed in Supplementary Table 3 . The TaqMan reaction mixture (10 μl) contained 4.5 μl of complementary DNA was mixed with 0.5 μl 20× TaqMan Gene Expression Assays and 5 μl of 2× TaqMan Universal PCR Master Mix (Applied Biosystems). Hypoxanthine phosphoribosyltransferase (HPRT) and alanyl-tRNA synthetase (AARS) probes were used in parallel assays performed in each sample and used as housekeeping controls. The reactions were performed using the following parameters: 50 °C for 2 min, 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 60 °C for 1 min. All TaqMan PCR data were captured using the Sequence Detector Software (SDS v.1.9, Applied Biosystems). Taqman probes and context sequences are listed in Supplementary Table 3 . Samples were analyzed with the double delta CT (ΔΔCT) method. Delta CT (ΔCT) values represent normalized target gene levels with respect to internal housekeeping controls (HPRT1 and AARS), selected for the replicating efficiency in human post-mortem brain tissue 50 . ΔΔCT values were calculated as the ΔCT of each test sample minus the mean ΔCT of the calibrator samples for each target gene. The fold change was calculated using the equation 2 (−ΔΔCT) . Results were analyzed with Kruskal-Wallis test followed by post hoc Mann-Whitney test. Differences between groups were considered statistically significant at a P value of <0.05.
Mice. Double chimeric transgenic APP;PS1 mice, expressing the human mutated APP (APP695swe) and presinilin1 (PS1-dE9) genes under the prion promoter that directs expression to the CNS 27 , were crossed with Sfrp1 +/-mice, generated as described 5 and maintained in B6/129 mixed background, to obtain APP;PS1;Sfrp1 −/− and APP;PS1;Sfrp1 +/+ mice. Initial breeding pairs of the APP;PS1 mice were kindly provided by I. Torres-Aleman, Instituto Cajal, CSIC, Madrid. Homozygous male mice between 1 and 20 months of age were used throughout the study, unless otherwise stated, with no inclusion/exclusion criteria other than genotype, sex and age. Within these criteria animals were randomly chosen among the available males. Animals were housed and treated according to European Communities Council Directive of 24 November 1986 (86/609/EEC) regulating animal research. All procedures were approved by the Bioethics Subcommittee of Consejo Superior de Investigaciones Científicas (CSIC, Madrid, Spain) and the Comunidad de Madrid under the protocol approval number PROEX 100/15; RD 53/2013. The number of animals used for each experiment is indicated in the figures or their legends. The minimum number of animals required in each experiment was predicted using the G3*Power 3.1 program, as detailed in the statistical section of this Methods.
Antibodies. The following monoclonal antibodies were used: mouse anti-APP (clone 22C11, N-terminal, 1:1,000, Chemicon, catalog no. MAB348, batch LV1634989), mouse anti-amyloid-β (clone 4G8), which recognizes amino acids 17-24 of the human and mouse amyloid-β (1:500, Covance, catalog no. SIG-39220, batch D11DF00836), mouse monoclonal anti-amyloid-β (clone 6E10), which recognizes amino acids 1-16 of the human amyloid-β and sAPPα (1:500, Covance, catalog no. SIG-39320), rabbit anti-amyloid-β (H31L21), which recognizes amino acids 36-42 of the human and mouse amyloid-β (1:1,000, Thermo Fisher, catalog no. 700254, batch RH240023), mouse anti-sAPPα (clone 2B3), which recognizes sAPPα (1:500, IBL, catalog no. 11088, batch 1l-227), rabbit anti-SFRP1 (1:2,000, Abcam, catalog no. ab126613), rat anti-CD45 (clone IBL-3/16, 1:500, AbDSerotec, catalog no. MCA1388), rat anti-LAMP1 (clone ID4B, 1:200, DSHB), mouse anti-αTubulin (clone B-5-1-2, 1:5,000, Sigma-Aldrich), mouse anti-NeuN (clone A60, 1:500, Millipore, catalog no. MAB377, batch LV1457494); rabbit anti-Axin2 (1:1,000, Abcam catalog no. ab109307; lot GR1783799020); mouse anti-Cdh2 (Clone 3B9, 1:500 Invitrogen catalog no. 180224; lot 1553634A). Rabbit polyclonal antibodies were the following: anti-sAPPβ (1:500, BioLegend, catalog no. 813401) anti-Aβ1-40/42 (1:500, Millipore, catalog no. AB5076, batch 2584867), anti-APP C-terminal (1:500, Sigma-Aldrich, catalog no. A8717, batch 045M4785V), antiSfrp1 (1:500, Abcam, catalog no. ab4193), anti-GFAP (1:3,000, DAKO, catalog no. Z0334, batch 20028619), anti-Iba1 (1:2,000; Wako, catalog no. 019-19741, batch LKG5732); anti-BACE1 (1:1,000 Calbiochem catalog no. 195111, batch D0903996), anti-amyloid fibril OC (1:1,000; Millipore, catalog no. AB2886), antiamyloid oligomer αβ (A11; 1:1,000; Millipore, catalog no. AB9234, batch 3108666). Chick anti-βGal (1:500, Abcam, catalog no. ab9361, batch 365032). Secondary antibodies were the following: Alexa-488, Alexa-594-conjugated affinity-purified secondary anti-rabbit or mouse antibodies (1:2,000 Molecular Probes) or biotinconjugated anti-rabbit and anti-mouse IgG (1:500; Jackson ImmunoResearch, Cambridgeshire, UK), visualized with peroxidase-conjugated streptavidin (1:500, Jackson ImmunoResearch). All antibodies used in the study were validated by the commercial sources, except for the monoclonal antibody against SFRP1 we generated that are validated in Supplementary Fig. 1 .
Generation of anti-SFRP1 monoclonal antibodies. This is detailed in the Supplementary Methods.
Semi-quantitative PCRs. These are detailed in the Supplementary Methods.
In situ hybridization and immunohistochemistry. Mice were anesthetized with pentobarbital or ketamine/xilacine and transcardiacally perfused with 4% paraformaldehyde in phosphate buffer. Brains were extracted and post-fixed for 24 h at 4 °C. Tissue was then washed in PBS, incubated in a 30% sucrose/ PBS solution, embedded and frozen in a 7.5% gelatin, 15% sucrose solution. ISH was performed with RNAscope 2.5 Duplex detection technology (ACDbio) in 10-15 μm cryostat sections, using a probe for mouse Sfrp1 mRNA (channel C1, detected in red) and a probe for mouse Iba1 mRNA (channel C2, detected in blue). ISH for Sfrp1 was combined with immunohistochemistry (IHC) for GFAP as described below. IHC was performed on free-floating 50 μm vibratome or 6 μm paraffin sections from frontal human cortices and on 10-15 μm mouse brain cryostat sections. In the case of amyloid-β and Sfrp1 co-immunostaining, sections were treated in 90% formic acid for 10 min or boiled in citrate buffer (10 mM, pH:6) and then with 0.3% H 2 O 2 in methanol for 20 min. After several washes in PBS, sections were treated with M.O.M. blocking reagent (Vector Labs), incubated in PBS containing 0.5% Triton X-100, 5% FCS and 1% BSA for 2 h at room temperature, and thereafter with anti-Sfrp1 10.5.6 monoclonal antibody (1:2,000, Supplementary Methods) or anti-Sfrp1 rabbit polyclonal (Abcam) and anti-Aβ 1-40/42 (4G8 or rabbit polyclonal, 1:500) antibodies diluted in the same buffer overnight at 4 °C. After washing, sections were incubated with secondary antibodies for 2 h. APs in human and mouse tissues were visualized with 0.01% ThioflavinS (SigmaAldrich) in 50% EtOH and differentiated in 50% EtOH. In the case of Sfrp1 and GFAP or Iba1 and Aβ42 and CD45 or LAMP1 co-immunostaining, sections were pretreated as above and incubated with appropriate antibodies overnight at 4 °C. Tissue was analyzed with fluorescent conventional or confocal microscopy.
Synaptosome isolation. Synaptosomes were isolated from WT and APP;PS1 hemispheres as previously described 51 with minor modifications. The synaptosome-enriched fractions were solubilized in 147 mM NaCl, 3 mM KCl, 10 mM Glucose, 2 mM MgSO 4 , 2 mM CaCl 2 , 20 mM Hepes, 0.1% SDS, 0.1% NaDeoxicolate, 1% Triton X-100 plus protease inhibitors (Roche).
Immunoprecipitation and western blot analysis. To detect APP and its derived proteolytic peptides, cortical hemispheres from WT, APP;PS1;Sfrp1 −/− and APP;PS1 mice were homogenized in Tris-NaCl soluble buffer with protease inhibitors and centrifuged. The resulting pellets were homogenized in RIPA lysis buffer with protease inhibitors and processed for immunoprecipitation as described 52 with the following modifications. After immunoprecipitation with anti-amyloid-β 6E10 monoclonal antibody, beads were resuspended in NuPAGE LDS sample buffer (4×) (Thermo Fisher) without 2-mercaptoethanol, heated at 97 °C on a shaker for 10 min, centrifuged and the supernatants were resolved in 10-20% Tris-Tricine gels (Bio-Rad). Gels were transferred onto nitrocellulose membranes by dry iBlot (Invitrogen). The membranes were then boiled in PBS for 7 min, stained with Ponceau red solution, washed in TBS-T and incubated sequentially in PBS containing 0.05% Tween, 10% non-fat milk and 0.1% BSA and then with 6E10 monoclonal antibody solution, followed by peroxidase-conjugated secondary antibody. The signal was visualized with the ECL Advanced Western Blotting Detection Kit (Amersham). Membranes were stripped with Re-Blot Plus Strong Solution (Millipore) and reblotted with the 4G8 monoclonal antibody or anti-APP-C-terminal polyclonal antibody. To detect Sfrp1-amyloid-β interaction, co-immunoprecipitation studies were performed using RIPA brain extracts from APP;PS1 and APP;PS1; Sfrp1 −/− using either anti-amyloid-β (6E10), anti-Sfrp1 or IgG isotype control antibodies. Co-immunoprecipitation was analyzed by western blot with either anti-Sfrp1 or anti-amyloid-β antibodies, respectively. Co-immunoprecipitation studies to determine the possible interaction of Sfrp1 to ADAM10 in the synaptosome-enriched fraction from WT and APP;PS1 were performed with the same procedure. To detect APP and the derived proteolytic peptides in human tissue by western blot, entorhinal cortex samples were 1 nature research | reporting summary The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Data analysis
We used common and available softwares as follow. Rreely available statistical power analysis program G Power (version 3.1.9.2). ImageJ software (U.S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij). SPSS statistical package version 20.0. This information is also indicated in the methods.
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